Although positron-emission tomography (PET) with labeled fatty acid delineates infarct size and permits qualitative assessment of fatty acid utilization, quantification of oxidative metabolism is limited by complex alterations in the pattern of utilization of fatty acid during ischemia and reperfusion. Because metabolism of acetate by myocardium is less complex than that of glucose or palmitate, we characterized kinetics of utilization of radiolabeled acetate in 37 isolated rabbit hearts perfused with modified Krebs-Henseleit buffer and performed a pilot tomographic study in man.
oxidation and from aerobic to anaerobic glycolysis in hearts rendered ischemic preclude accurate estimation of oxidative metabolism by residue detection of any one of the tracers conventionally used in PET such as 18Fdeoxyglucose or "C-palmitate evaluated in isolation.5 Quantification of regional oxidative metabolism with a single tracer would be useful to delineate the extent and distribution of jeopardized ischemic myocardium, objectively evaluate its response to interventions such as coronary thrombolysis or angioplasty, and characterize effects of physiologic and pharmacologic interventions designed to salvage ischemic tissue or metabolic function. Judging from information available and results of previous studies,4-8 we considered the possibility that overall citric acid cycle flux and hence overall oxidative metabolism could be measured externally from the rate of myocardial clearance of radiolabeled acetate.
Citric acid cycle flux is not estimable from measurements of myocardial utilization of radiolabeled palmitate for several reasons, including the dependence of fatty acid utilization on the availability and/or inhibitory effects of alternative substrates.9 Backdiffusion of nonmetabolized "C-palmitate in the presence of myocardial ischemia contributes up to 50% of the total clearance of radioactivity from the myocardium and thereby overestimates overall rates of oxidation. 7 In addition, preferential inhibition of /8-oxidation occurs with ischemia,8 dissociating rates of /3-oxidation from rates of citric acid cycle turnover. Similar difficulties are encountered with glucose or glucose analogs. Thus glucose labeled with "C undergoes disparate metabolic fates depending on physiologic conditions, including incorporation into glycogen; conversion to constituents of lipid, carbohydrate, and protein intermediates; anaerobic glycolysis; and flux through the citric acid cycle. Metabolism of deoxyglucose labeled with fluorine-18 is somewhat more constrained but indicative only of glucose uptake rather than myocardial oxygen utilization per se. The kinetics of both tracers are influenced markedly by arterial glucose concentration, neurohumoral environment, and prevailing concentrations of other substrates.9
To overcome limitations inherent in the use of labeled glucose or fatty acid alone for assessment of myocardial oxidation, we performed the present study with acetate, which is readily oxidized to CO2 via the citric acid cycle'0-13 and exhibits essentially one pathway of metabolism in the heart. 14 We considered it likely that these characteristics would make radiolabeled acetate particularly suitable as a tracer for quantification of net myocardial oxidative metabolism in selected regions of the heart under diverse conditions. Although "C-acetate has been used in preliminary studies of experimental animals and patients, kinetics have not been related to oxidative metabolism. '5-17 Accordingly, the present study was undertaken to determine whether externally detected clearance of "C-acetate would provide a quantitative index of myocardial oxidative metabolism. Because of the short half-life of "C (20.4 min), "4C-acetate was used in initial studies in which the biochemical fate of tracer was defined. Subsequent results were obtained by external detection of radioactivity from "C-acetate. Our objectives were to (1) define the extraction of 14C-acetate under diverse conditions ofmetabolism and flow, (2) determine relationships between the rate of efflux of 14CO2 in venous effluents, reflecting oxidation of "4C-acetate, and oxygen consumption, and (3) define relationships between the externally detectable clearance of myocardial "C radioactivity and myocardial oxygen consumption in isolated perfused rabbit hearts subjected to defined flow, oxygenation, and delivery of tracer. An additional pilot study was performed to assess the feasibility of imaging human myocardium with PET and "C-acetate.
Methods
Male New Zealand rabbits weighing 3 to 5 pounds were stunned with a blow to the head. Heart were rapidly excised and perfused with nonrecirculating, oxygenated (95% 02/5% C02) modified Krebs-Henseleit perfusate containing 400 gM albumin, 400 gM palmitate, 5 mM glucose, and 70 mU/liter insulin.
Hearts were paced at a rate of 180 beats/min with a right atrial bipolar electrode. Left ventricular pressure was monitored continuously with a fluid-filled latex balloon inserted through the left atrium. The first derivative of left ventricular pressure (dP/dt) and coronary perfusion pressure were also recorded. The left ventricular pressure-time index was calculated from the product of the area under the left ventricular systolic pressure curve and heart rate. 18 The pulmonary artery was cannulated for collection of coronary venous effluent. Oxygen utilization was calculated from the product of arteriovenous oxygen content difference per milliliter of perfusate and flow, normalized for heart weight. 18 Experimental procedure. To determine the steady-state extraction fraction of 14C-acetate and production of '4C02 under diverse conditions, 1 hearts were perfused with 20 MCi/liter l-14C-acetate (specific activity 56 mCi/mmol; New England Nuclear) over a period of 30 min.
The extraction fraction was calculated from the arteriovenous 14C-acetate difference as a percentage of arterial '4C-acetate.
High-pressure liquid chromatography (see below) was used to separate 14C-acetate, which was then quantified by gamma counting. Conditions investigated were normal flow (20 ml/min, n = 4) and reduced flow (2 ml/min, n 4) with and without the addition of 50 gM of unlabeled sodium acetate. The extraction fraction was measured at 20 to 30 min in control hearts and at both 10 and 30 min in ischemic hearts. The extraction fraction was also measured in hearts reperfused at control flow rates after 60 min of ischemia (n = 3), 20 to 30 min after commencement of '4C-acetate infusion.
In 16 additional hearts studied under control conditions, with hypoxia (flow rate of 20 ml/min with hypoxic media), with ischemia, or with reperfusion after ischemia, the rate of oxidation of 14C-acetate was determined based on the measured rate of efflux of 14C02 in the venous effluent over a 40 min interval after a 2 min infusion of 15 ,uCi 14C-acetate. The 2 min infusion interval was selected based on results in pilot studies of the arterial time-activity curve after intravenous administration of tracer in vivo.
After the completion of these initial studies. 0.5 mCi ' Cacetate and 15 ,uCi 14C-acetate were infused simultaneously over 2 min in 10 hearts. Clearance of ''C radioactivity was measured externally by residue detection, and the rates of efflux of total 14C and '4CO2 were determined in the effluent over 20 to 40 min.
In four of these hearts, the "C myocardial residue-time activity curve was determined at three different workloads induced by changing preload and heart rate (low and medium workload) and by infusion of isoproterenol (5 X 10-7M, high workload).
Measurement of "4CO2 radioactivity. Coronary venous effluent was collected at 1 min intervals into tubes containing sodium hydroxide to trap 14CO2. Total 14C radioactivity was determined by placing 1 ml of perfusate in 1 ml of Protosol (New England Nuclear) and adding 10 ml of Aquasol II (New England Nuclear) before /3-scintillation spectrometry. A duplicate sample was treated with 0.25 ml of 5N HCl and allowed to stand overnight on ice (to minimize loss of "4C-acetate) before spectrometry. Assay of standards verified greater than 99.9% loss of 14C-bicarbonate and greater than 98% retention of 14C-acetate under these conditions. The 14C02 content per milliliter of perfusate was calculated as the difference between total and residual radioactivity after treatment with HCl.
Measurement of "'C-labeled metabolites in venous effluent. To characterize conversion of labeled acetate to metabolites other than labeled C02, albumin was precipitated in samples of venous effluent with an equal volume of 10% perchloric acid. The samples were centrifuged, and supematant fractions were allowed to stand on ice overnight for dissipation of 14Co2. Samples were stored at -700 C. Metabolites were separated with a SpectraPhysics high-pressure liquid chromatography (HPLC) system (San Jose, CA) and detected with a Waters Differential Refractometer. Optimal separation of standards was accomplished with two organic acid columns in sequence (Biorad Aminex HPX 87H and Benson 0A850) with 0.O0N H2S04 at a flow rate of 0.5 ml/min.'9 Retention times of individual citric acid cycle intermediates were determined, as were those for pyruvate, lactate, acetoacetate and ,3-hydroxybutyrate. Because retention times for some species overlapped, additional separation for acetate and acetoacetate was accomplished with a C 18 reverse-phase column (LiChrosorb RP 18, E. Merk, Darmstadt, W. Germany) in combination with an organic acid column. Fractions of effluent separated on the basis of measured retention times of each standard were collected for assay of radioactivity.
Lactate and glucose were assayed conventionally with commercially available enzymatic assay kits (Behring Diagnostic, La Jolla, CA). Utilization and production of substrate were calculated from the product of arteriovenous concentration differences and flow and normalized for heart weight. Myocardial lipid was extracted by the Bligh and Dyer procedure,20 and the percentage of 14C radioactivity in the lipid phase relative to total myocardial radioactivity was determined.
Synthesis of "C-acetate. A modification of the method developed by Pike et al.2' was used to prepare ''C-acetate.
"C-labeled carbon dioxide was prepared by the 14N (p,a) "C reaction in the Washington University Medical Center cyclotron and bubbled through 3 ml of a 0. IM solution of methylmagnesium bromide (Aldrich Chemical Co., Milwaukee) in diethyl ether. The product was hydrolyzed with 6 ml of 6N hydrochloric acid. An additional 6 ml of diethyl ether was then added. The sample was vortexed, and the organic layer was allowed to separate from the aqueous layer. The latter was discarded, and 10 ml of 0.9% sodium bicarbonate was added to the organic layer and vortexed. After separation, the aqueous layer was transferred and bubbled with nitrogen at 500 C. Sterility was maintained by serial filtration through 0.45 and 0.2 ,um filters. Radiochemical purity, determined by HPLC, was consistently greater than 96%. Estimated specific activity was greater than 1 Ci/mmol.
Residue detection of`C activity. Annihilation photons were detected with two sodium iodide crystals placed 180 degrees apart across the heart. Coincidence counts were detected with an Ortec fast coincidence counter. Singles counts from one sodium iodide crystal and coincidence counts from both were recorded on-line with a Digital Equipment Corp. RX-08 minicomputer. Data were subsequently decay-corrected off-line. Clearance data were fitted with a multiexponential curve-fitting routine. Although an attempt was made to fit biexponential solutions to all data, only monoexponential solutions were apparent in ischemic and hypoxic hearts. The biological halftime (t½A) was calculated from the rate constant (k) and the relationship t'A = In2/k. The relative magnitude of each phase of a biexponential fit was calculated by back-extrapolation of the monoexponential slope of each phase to the time of completion of infusion of`1C-acetate as a percentage of the sum of both phases at that time.
Statistical analyses. Data are expressed as mean ± SD. Multiple comparisons of unpaired and paired samples were analyzed by analysis of variance followed by t tests corrected for the number of comparisons by the Bonferroni method.22 Linear regression was calculated by the least-squares method.
Results
Hemodynamics, flow, and oxygen consumption. Hemodynamics and substrate utilization for steady-state studies (group 1) and clearance studies (group 2) with 14C-acetate are presented in table 1. Hemodynamics were constant throughout the interval of evaluation in control hearts. Flow was reduced by 85% to 90% in ischemic hearts, and myocardial oxygen consumption was diminished proportionately. Heart rate diminished by approximately 40% because of atrioventricular block. Hearts reperfused after 60 min of ischemia Values are mean ± SD. HR = heart rate; LVEDP = left ventricular end-diastolic pressure; dP/dt = first derivative of left ventricular pressure; LVPTI = left ventricular pressure-time index; MVO2 = myocardial oxygen consumption. Ap < .01 compared with control. exhibited left ventricular pressure-time index values and oxygen consumption similar to those in control hearts but at marginally higher left ventricular enddiastolic pressure.
Utilization of glucose was depressed in ischemic hearts. However, the reduction was not statistically different compared with control hearts in part because of the increased extraction fraction of glucose at low flow. Also, glucose utilization varied considerably in control hearts because of low extraction fraction at high flow rates. Lactate production was significantly higher in hypoxic compared with control hearts.
Steady-state utilization of acetate. The steady-state extraction fraction of 14C-acetate was determined in 1 1 isolated rabbit hearts subjected to a wide range of flow and altered metabolic states. Extraction fraction of 14C-acetate in hearts perfused at a control flow rate of 20 ml/min with media without added unlabeled sodium acetate averaged 63.4 ± 9.5%. In ischemic hearts it averaged 94.9 ± 1.1%. Addition of a physiologic concentration (50 ,uM) of unlabeled sodium acetate had no effect on the extraction fraction (59.6 + 1.6% in control hearts, 93.4 + 0.7% in ischemic hearts). Thus, in hearts perfused with media with or without unlabeled acetate, the extraction fraction was significantly higher with ischemia (p < .001). The extraction fraction of '4C-acetate remained constant throughout the interval of ischemia. Hearts reperfused at a flow of 20 ml/min after 60 min of ischemia exhibited extraction fractions similar to those in controls (54.8 ± 4.0%; n = 3, p= NS).
Steady-state production of '4C02 resulting from oxidation of 14C-acetate in control and reperfused hearts generally occurred within 15 min after onset of perfusion with 14C-acetate and accounted for 86 + 7% of 14C-acetate uptake. The rate of production of 14C02 in ischemic hearts continued to increase throughout the period of perfusion but appeared to reach steady state by 25 min. The delay to equilibrium was presumably caused by the slower rate of turnover of the citric acid cycle during ischemia.
Rate of oxidation of "4C-acetate. The rate of efflux of '4C02 in venous effluent was characterized under a variety of conditions after a 2 min infusion of 14Cacetate. Efflux of' 4C02 reached a maximum 2.3 + 0.8 min after the end of the infusion in control hearts (n = 10) but was delayed to 1 1.8 ± 2.6 min in ischemic hearts (n = 10). Efflux was subsequently biexponential in control and reperfused hearts (Figure 1, a) , consisting of a dominant rapid phase and a smaller slower phase of efflux. Efflux was monoexponential in ischemic and hypoxic hearts ( figure 1, b ). The half-times Prediction of "4CO2 efflux based on total venous efflux of 14C radioactivity. The rate of efflux of total 14C radioactivity in the venous perfusate was used to estimate the rate of '4CO2 efflux, which in turn was used to determine whether acetate oxidation could be measured externally by residue detection of myocardial "C-acetate. Because dynamic studies with PET define total clearance of tracer from myocardium but not clearance of "'CO2 specifically, this comparison was performed to identify potential limitations of estimating oxidation of "C-acetate from analysis of myocardial residue time-activity curves.
Half-times of the rapid phase of "4CO2 efflux and total "'C efflux were almost identical in control hearts whether or not stimulation with isoproterenol was used (figure 3). A similar concordance was seen in reperfused hearts and in hypoxic hearts (figure 3). In ischemic hearts, the half-times for "4CO2 efflux (15.8 ± 4.8 min) were slightly longer than those for total 14C efflux (14.7 ± 3.4 min) although the difference was not statistically significant. This modest discrepancy was attributable to a lower fraction of '4C02 comprising total 14C radioactivity in the venous effluent ( figure 4) .
In control and reperfused hearts, nearly all radioactivity (96.0 ± 1.1%) in the venous effluent was in the form of 4 CO2 during the first 20 min ( figure 4) . In contrast, in ischemic hearts, 14C02 contributed 75.7 ± 7.2% of total venous radioactivity during the period of monoexponential clearance of "4CO2 10 to 30 min after the completion of the infusion of "4C-acetate ( figure 4) . Thus, despite the presence of backdiffused "4C-acetate or metabolites of "4C-acetate in the venous effluent of ischemic hearts, the disparity between calculated 14C02 efflux and total "4C efflux was small.
Metabolites of "4C-acetate. The metabolites in the venous effluent were separated by HPLC to determine whether radioactivity that was not accounted for by 14CO2 was attributable to backdiffused "4C-acetate or to metabolites. In the effluent from a control heart, 4 min after the completion of the infusion of 14C-acetate 96% of the venous effluent was in the form of "'CO2.
Nonmetabolized "4C-acetate comprised 19% of non-"4CO2 activity (thus 0.8% of total effluent radioactivity). Thirty-five percent of non-CO2 activity was attributable to ketones, specifically 14C-,3 hydroxybutyrate (24%) and 14C-acetoacetate (11%). In ischemic hearts at 4 min after the completion of tracer infusion, 44% of venous effluent was in the form of 14CO2. Backdiffused "4C-acetate contributed 3.3 ± 1.3% of non-14"C2 activity, whereas 14C-,3 hydroxybutyrate accounted for 73.7 ± 6.4% and "4C-acetoacetate for 0.7 ± 1.2% (n = 3). After 14 min, 80% of total radioactivity was in the form of "4CO2. Of non-'4C02 activity, 1 ± 0.9% was attributable to "4C-acetate, whereas "4C-,3 hydroxybutyrate comprised 40.6 ± 10.6% and 14C-acetoacetate 3.6 ± 2.7%. The remaining 14C metabolites were largely citrate, succinate, and lactate Values are means ± SD. In control hearts, nearly all radioactivity (96.0 ± 1 .1 %) in the venous effluent was in the form of 14CO0. In ischemic hearts, 2 to 4 min after 14C-acetate infusion 44% of effluent was in the form of 14CO'. This production increased to greater than 80% (see figure 4 ) after 14 min.
with percentages of radioactivity increasing in each from 6 to 12 min after completion of the infusion with '4C-acetate (table 2) . The distribution ofthe 14C label between the aqueous and lipid fraction of myocardium was determined in four hearts after completion of the 14C-acetate clearance studies. The percentage of total radioactivity in the lipid fraction of two control hearts (0% and 12.6%) did not differ significantly from those in two ischemic hearts (2.8% and 5.5%).
External assessment of clearance of "C-acetate. Clearance of "C-acetate was measured in six control and four ischemic hearts by analysis of externally detected myocardial residue time-activity curves and compared with the clearance of 14C-acetate measured by direct assay of radioactivity in the effluent. In control hearts, 1"C-acetate clearance was measured at 14 workloads and compared with oxygen consumption. The decline in myocardial residue counts as a function of time was biphasic (figures 5, a and b) and data from control hearts could be closely fitted with biexponential solutions. The biexponential clearance of the myocardial residue suggested that the "C label was present within the myocardial cell in at least two separate pools, one clearing rapidly and one slowly. The relative size of each was approximated from the size of each phase of the biexponential curve. Clearance was predominantly due to the rapid phase, since the slowly clearing pool accounted for only 7.4 + 3.0% of total "C radioactivity. No significant change in the size of this pool was seen with changes in cardiac work or oxygen consumption. The rate constant of the initial phase of clearance increased with increased workload in parallel with increased oxygen consumption ( figure 5, a and b) .
No change in the rate constant of the late phase was seen with increased workload (t',2 28.5 + 16.0 min).
The myocardial residue time activity curve in four ischemic hearts, analyzed over the same interval as that used to calculate 14Co2 efflux (i.e., 10 to 40 min after "C-acetate infusion), was monoexponential ( figure  5, c) . 692 In all hearts, the rate constant of the initial phase of the residue clearance was very similar to and correlated closely with total efflux of 14C ( figure 6 , a, r = .99, p < .001). Consistent with the close correlations between the rate of total 14C efflux, 14Co2 efflux and oxygen consumption, "C-acetate clearance and oxygen consumption correlated closely as well (figure 6, b; r = .95, p < .001).
"C-acetate residue curves in ischemic hearts were analyzed over the interval in which efflux of "CO2 was monoexponential. Thus the first 10 min of the residue curve were excluded. However, sampling intervals would be difficult to discern in clinical studies from inspection of residue curves only. To determine the error involved when an earlier interval was used, we analyzed rates during the first 20 min of the residue curves in ischemic hearts as well. No significant differences were observed for half-times from this interval (19.9 ± 2.5 min compared with 20.3 ± 1.9 min). Thus, although oxidation of acetate and production of CO2 are retarded with ischemia, the interval selected for calculation of rate constant does not appear to be critical.
PET. Although this study was designed primarily to characterize the suitability of radiolabeled acetate as a tracer for use in estimating myocardial oxygen consumption under diverse conditions in isolated perfused hearts, its ultimate objective was to initiate development of an approach applicable to intact hearts in vivo in experimental animals23 and in patients evaluated by PET. Accordingly, the feasibility of imaging human myocardium after intravenous administration of 0.3 to 0.4 mCi/kg "C-acetate was explored. Images of "1C acetate accumulation in myocardium were readily acquired over brief imaging intervals averaging 60 to 120 sec. Myocardial residue time activity curves were generated from regions of interest encompassing the left ventricular wall in one midventricular slice. Rapid the rapid phase increased from 0.23 to 0.49 min-' with isoproterenol. Clearance from the ischemic heart (c) was monoexponential. Fits were made to coincide with the monoexponential efflux of "CO2, from 14 to 40 min in this example, as shown by the solid line. radioactivity from myocardium was 10.5 min in this example from a normal subject. In view of these results, it appears likely that quantitative estimation of clearance of "C-acetate from selected regions of myocardium and hence estimation of regional myocardial oxygen consumption will be possible in patients within the spatial and temporal limitations of the particular tomographic instruments used.
Discussion
Although acetate is a substrate known to be utilized readily by the heart, the low concentrations of acetate in human plasma (ranging from 25 to 100 ,uM)24' 25 dictate a low contribution of acetate to total myocardial substrate utilization. Nevertheless, acetate is oxidized readily by the heartl0- 12 and is capable of sustaining energy production when provided as a sole substrate. Availability of acetate also diminishes utilization of glucose and palmitate.°0' 1 Metabolism of acetate, Vol. 76, No. 3, September 1987 after activation to acetyl coenzyme A (CoA), is predominantly oxidative via the citric acid cycle. We postulated that the rate of oxidation of labeled acetyl CoA would indicate overall citric acid cycle flux. The latter would be an index of oxygen consumption and energy production, since oxidative phosphorylation is closely coupled to the citric acid cycle. However, minor changes in the ratio of citric acid cycle flux to oxygen consumption will result from variation in the proportions of individual substrates utilized by the heart. The extent of this variation is small, however, as shown by calculations of oxygen consumption resulting from complete oxidation of each major substrate serving as the source of acetyl CoA for the citric acid cycle. For example, oxidation of glucose, lactate, and palmitate consume 3.0, 3.0, and 2.9 moles of oxygen per mole of acetyl CoA utilized, respectively. With palmitate as the reference, oxygen consumption calculated from citric acid cycle flux would be over- OXYGEN CONSUMPTION (mi/gmn/min) FIGURE 6. a, Correlation between the rate constants for total 14C efflux and the rate constants of the "C residue time-activity curve from 10 hearts. Both rate constants were calculated from the rapid phase of biexponential curves. b, Correlation between myocardial oxygen consumption and the rate constant of the rapid phase of the externally detected myocardial residue time-activity curves in 18 studies after infusion of`C-acetate. estimated by 4% if glucose were the only substrate utilized. The same overestimation would be encountered if lactate were the only substrate utilized.
The rate of efflux of 14C02 after '4C-acetate infusion from myocardium perfused with media containing physiologic concentrations of glucose, palmitate, and acetate was found to correlate very closely with myocardial oxygen consumption. Despite some backdiffusion of '4C-acetate and modest efflux of labeled metabolites other than CO2 with ischemia, the rate of efflux of total 14C activity correlated very closely with efflux of "4CO2. Thus the rate of clearance of the myocardial residue after '4C-acetate correlated closely with myocardial oxygen consumption.
Metabolism of acetate. The pathways involved in ace-694 tate metabolism are limited in comparison with those involved in glucose or fatty acid metabolism. In contrast to the incorporation into lipid or conversion to ketone bodies in the liver, oxidation is the predominant mode of metabolism in myocardium. After the activation of acetate to acetyl CoA in the mitochondria, acetyl CoA is oxidized via the citric acid cycle. Rapid expansion of the normally small acetyl CoA pool by utilization of acetate may result in the reversible conversion to acetylcarnitine, providing a larger storage pool in the cytoplasm. In mitochondria, acetyl CoA can be incorporated into fatty acids by de novo synthesis or chain elongation. However, the extent of either is less than 1% in normoxic hearts.'2 Although the rate of incorporation can increase up to 12-fold in isolated perfused rat hearts with hypoxia, 26 incorporation into lipid as a percentage of total intracellular pool is small. Results with hearts from our study indicate that in ischemic hearts, in which lipid incorporation would be expected to be maximal, the majority of the 14C label remains in aqueous rather than the organic phase of extracts. Thus incorporation into lipid is minimal.
Studies with 13C-acetate and magnetic resonance spectroscopy have shown incorporation of label into amino acids via citric acid cycle intermediates (e.g., into glutamate from a-ketoglutarate).27' 28 Possibly the slow phase of the "C residue curve represents metabolism of either fatty acids or amino acids containing the "C label.
The conversion of pyruvate to acetyl CoA is essentially irreversible in animal tissues,29 limiting the diversity of metabolic end products of radiolabeled acetate. This is a major disadvantage of acetate as a tracer of overall oxidative metabolism in comparison with other tracers such as glucose, pyruvate, or lactate from which production and subsequent release of metabolites such as labeled alanine can distort relationships between clearance of the tracer and oxygen consumption. No equilibration between 13C-acetate and alanine has been found by magnetic resonance spectroscopy in the nonischemic perfused rat heart,27 suggesting that no exchange occurs with pyruvate.
The heart, unlike other organs such as the liver, does not generally produce ketone bodies.30 ' We identified production of small quantities of 14C-fl hydroxybutyrate and acetoacetate in both normoxic and ischemic hearts consistent with analyses of pig heart extracts,32 isolated rat heart mitochondria,33 and dog hearts rendered hypoxic. Implications for PET. Myocardial extraction of 14Cacetate was high despite the high flow rates required for normoxic perfusion of isolated hearts with buffer solu- Excellent contrast between rnvocardium and lung or blood pool is observed. The lateral left ventricular wall is to the right, apex is to the top. and septum is to the left. tions not containing erythrocytes. It is high also in human subjects. 35 Extraction increased further to 94% in ischemic hearts in our study because of the increased residence time of the tracer in the vasculature. Uptake was not diminished by increasing the concentration of acetate to that found in plasma in vivo.
Backdiffusion of '4C-acetate was modest even in ischemic hearts. In contrast, ''C-palmitate backdiffusion from ischemic canine hearts constitutes approximately 50% of efflux of radioactivity from the heart.7 Although release of labeled ketone bodies contributed 20% to 30% of total radioactivity in the venous effluent from ischemic hearts once maximum 14C02 production had been reached, it constituted approximately 39% during the first 10 min. Because the efflux of '4CO2 from 14C-acetate was delayed by ischemia, analysis of the residue curve earlier could potentially introduce error. However, we found that selection of the portion of the residue time-activity curve in ischemic hearts was not critical.
The high extraction fraction of ''C-acetate and the rapid decline of blood pool radioactivity in vivo augur well for tomographic imaging of the heart with " Cacetate. The increased extraction fraction in ischemic myocardium should facilitate tomography even when delivery is limited by low blood flow. Synthesis of "C-acetate is rapid with high radiochemical purity and high yields. Preliminary results with intravenous "Cacetate in canine23 and human myocardium document high-quality imaging and rapid clearance of the blood pool radioactivity. Because myocardial residue timeactivity curves can be measured easily with serial PET images and regional activity quantified over time, metabolism of ''C-acetate and hence myocardial oxy-Vol. 76. No. 3. September 1987 gen consumption should be quantifiable. Further validation of the approach developed will require extensive studies in vivo and evaluation of potential effects of changes of concentrations of substrates in plasma. Nevertheless, results of the present study suggest that PET with "C-acetate should permit accurate estimation of regional myocardial oxidative metabolism noninvasively.
